Association of Cystatin C with Metabolic Syndrome and Its Prognostic Performance in Non-ST-Segment Elevation Acute Coronary Syndrome with Preserved Renal Function
Joint Authors
Zheng, Wei
Li, Youmei
Li, Lufeng
Mao, Qi
Zhao, Xiaohui
Zhao, Ning
Wang, Yuqing
Xiang, Chaojun
Xu, Shangcheng
Source
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-11, 11 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-06-16
Country of Publication
Egypt
No. of Pages
11
Main Subjects
Abstract EN
Objective.
The underlying mechanisms by which cystatin C affects cardiovascular disease (CVD) are not very clear.
Metabolic syndrome (MetS) is a cluster of risk factors that increase the risk of CVD.
Here, we aimed to investigate the association of cystatin C with metabolic syndrome and cardiovascular outcomes in non-ST-segment elevation acute coronary syndrome (NSTE-ACS) with preserved renal function.
Methods.
In total, 422 NSTE-ACS patients with preserved renal function were enrolled to examine the association of cystatin C with MetS.
MetS was defined based on the NCEP-ATP-III guidelines.
Major adverse cardiovascular events (MACEs) were also evaluated, which included cardiac death, nonfatal myocardial infarction (MI), target vessel revascularization (TVR), heart failure, and nonfatal stroke.
All patients underwent a 12-month follow-up for MACEs after admission.
Results.
Cystatin C was significantly correlated with metabolic risk factors and inflammation markers.
The prevalence of MetS and MACEs correlated with cystatin C levels.
Cystatin C showed a strong diagnostic performance for cardiovascular risk factors and outcomes in ROC analysis.
After adjustment for multiple risk factors, cystatin C level was independently associated with MetS (OR 2.299, 95% CI 1.251–4.225, and P = 0.007).
During a 12-month follow-up, the patients with high cystatin C level and MetS had higher incidence of MACEs (Log-rank = 24.586, P < 0.001) and cardiac death (Log-rank = 9.890, P = 0.020) compared to the others.
Multivariate Cox analysis indicated that cystatin C level was an independent predictor of MACEs (HR 2.609, 95% CI 1.295–5.257, and P = 0.007).
Conclusion.
Cystatin C may be an independent predictor of metabolic syndrome and therefore valuable for management of NSTE-ACS patients.
Further multicenter, large-scale studies are required to assess the implication of these results.
American Psychological Association (APA)
Mao, Qi& Zhao, Ning& Wang, Yuqing& Li, Youmei& Xiang, Chaojun& Li, Lufeng…[et al.]. 2019. Association of Cystatin C with Metabolic Syndrome and Its Prognostic Performance in Non-ST-Segment Elevation Acute Coronary Syndrome with Preserved Renal Function. BioMed Research International،Vol. 2019, no. 2019, pp.1-11.
https://search.emarefa.net/detail/BIM-1127968
Modern Language Association (MLA)
Mao, Qi…[et al.]. Association of Cystatin C with Metabolic Syndrome and Its Prognostic Performance in Non-ST-Segment Elevation Acute Coronary Syndrome with Preserved Renal Function. BioMed Research International No. 2019 (2019), pp.1-11.
https://search.emarefa.net/detail/BIM-1127968
American Medical Association (AMA)
Mao, Qi& Zhao, Ning& Wang, Yuqing& Li, Youmei& Xiang, Chaojun& Li, Lufeng…[et al.]. Association of Cystatin C with Metabolic Syndrome and Its Prognostic Performance in Non-ST-Segment Elevation Acute Coronary Syndrome with Preserved Renal Function. BioMed Research International. 2019. Vol. 2019, no. 2019, pp.1-11.
https://search.emarefa.net/detail/BIM-1127968
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1127968